| Drug Name |
Trametinib |
| Drug ID |
BADD_D02257 |
| Description |
Trametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013 [L2727].
The U.S. Food and Drug Administration approved [DB08912](Tafilnar) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive) [L2726].
Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health (NIH) estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for approximately 1 to 2 percent of all thyroid cancers [L2726]. |
| Indications and Usage |
Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [FDA].
In May 2018, it was approved for use with [DB08912] for the treatment of treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2726]. |
| Marketing Status |
approved |
| ATC Code |
L01EE01 |
| DrugBank ID |
DB08911
|
| KEGG ID |
D10175
|
| MeSH ID |
C560077
|
| PubChem ID |
11707110
|
| TTD Drug ID |
D04XVN
|
| NDC Product Code |
0078-1105; 73309-005; 0078-1112; 12064-021; 52482-014; 0078-0668; 12064-022; 54893-0062; 86036-018; 0078-0666; 0078-1161 |
| UNII |
33E86K87QN
|
| Synonyms |
trametinib | JTP 74057 | JTP74057 | JTP-74057 | GSK 1120212 | GSK1120212 | GSK-1120212 |
